ZBH Lags Peers Into Q3 Print With Options Skewing Cautious

Zimmer Biomet fell 4.1% over the past week, a steeper drop than the median decline of 1.7% among its closest peers. Stryker shed 5.0% and Globus Medical lost 4.1%, so the orthopedic space broadly weakened, but ZBH underperformed even that challenged cohort. Medtronic held relatively firm at down 1.2%, and Abbott gained 2.4%, widening the gap further. ZBH now trades at $94.52, down 3.0% in the last session alone.

Options positioning reflects that caution. The put/call ratio of 1.23 is running above its 20-day average of 1.14, a moderate elevation rather than an extreme reading. The 52-week range runs from 0.10 to 2.29, so there is room for sentiment to shift sharply in either direction. The borrow market, by contrast, offers no signal: availability is exceptionally loose at around 1,289% of short interest, meaning lenders hold roughly 13 shares for every one already borrowed. Short interest at 4.3% of the free float is modest and has eased about 5% over the past month, so there is no meaningful short-side pressure heading into the report.

The analyst community holds a buy consensus with a mean target of $106.90, implying about 13% upside from current levels. The debate centres on execution rather than market position. The bull argument rests on ZBH's global scale in large-joint reconstruction, the Paragon 28 acquisition adding growth, and the potential for margin improvement as the distributor-to-direct salesforce transition progresses. The bear case points to two large account losses disclosed in Q1, a US knees growth rate of only 2.2%, and management's own guidance that the salesforce overhaul will not be complete until end-2027. Barclays initiated coverage earlier in October at Equal-Weight with a $100 target, roughly in line with where the stock is now, a measured entry point that frames near-term upside as limited unless execution improves.

Dodge & Cox remains the standout institutional holder at 12.6% of shares. Its most recent 13G/A, filed in August, showed the stake had increased from 11.2% to 12.5%, a meaningful addition that signals conviction in the value case even as the stock has traded below most analyst targets for much of 2026. Capital Research and Management added over 3 million shares in the quarter ending July, another notable accumulation. The activist register carries no Schedule 13D filings; all large holders are passive. As last disclosed, stakes are around the 5% threshold and holders dropping below may not file again.

Wednesday's print will test whether the underlying procedure volume and the US knee franchise can show a cleaner growth rate, free of the account-loss distortions and one-time tariff credits that complicated the Q1 comparison.